- Home
- TYGO vs ELDN Comparison
TYGO vs ELDN Comparison
Compare TYGO & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- ELDN
- Stock Information
- Founded
- TYGO 2007
- ELDN 2004
- Country
- TYGO United States
- ELDN United States
- Employees
- TYGO N/A
- ELDN N/A
- Industry
- TYGO Semiconductors
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- TYGO Technology
- ELDN Health Care
- Exchange
- TYGO Nasdaq
- ELDN Nasdaq
- Market Cap
- TYGO 116.0M
- ELDN 120.8M
- IPO Year
- TYGO N/A
- ELDN N/A
- Fundamental
- Price
- TYGO $1.77
- ELDN $1.59
- Analyst Decision
- TYGO Strong Buy
- ELDN Strong Buy
- Analyst Count
- TYGO 1
- ELDN 3
- Target Price
- TYGO $6.00
- ELDN $11.00
- AVG Volume (30 Days)
- TYGO 630.6K
- ELDN 4.1M
- Earning Date
- TYGO 10-28-2025
- ELDN 11-14-2025
- Dividend Yield
- TYGO N/A
- ELDN N/A
- EPS Growth
- TYGO N/A
- ELDN N/A
- EPS
- TYGO N/A
- ELDN N/A
- Revenue
- TYGO $90,781,000.00
- ELDN N/A
- Revenue This Year
- TYGO $95.15
- ELDN N/A
- Revenue Next Year
- TYGO $21.54
- ELDN N/A
- P/E Ratio
- TYGO N/A
- ELDN N/A
- Revenue Growth
- TYGO 97.41
- ELDN N/A
- 52 Week Low
- TYGO $0.58
- ELDN $1.35
- 52 Week High
- TYGO $4.50
- ELDN $5.08
- Technical
- Relative Strength Index (RSI)
- TYGO 39.87
- ELDN 31.97
- Support Level
- TYGO $1.59
- ELDN $1.35
- Resistance Level
- TYGO $4.50
- ELDN $1.70
- Average True Range (ATR)
- TYGO 0.37
- ELDN 0.25
- MACD
- TYGO -0.03
- ELDN -0.08
- Stochastic Oscillator
- TYGO 6.70
- ELDN 19.05
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.